Boris D. Juelg, M.D. Ph.D.

Lab Info:

Principal Investigator: Boris D. Juelg, M.D. Ph.D.

Office/Location: 400T-8-882

Phone: (857) 268-7088

Email: bjulg@partners.org

Category: Members

Dr. Juelg is interested in applying new technologies to decipher the complex and heterogeneous CD8+ T-cell responses induced by vaccination while comparing it to natural HIV infection. In collaboration with Dr. Chris Love at the Massachusetts Institute of Technology he has developed a platform for the high-throughput analysis of single cytotoxic T-cells. Using this and other newer technologies(Time-of-Flight mass spectrometry (CyTOF), RNA-seq etc.), Dr. Juelg aims at defining T-cell subsets and specific CD8+ T-cell signatures associated with viral control and/or protection in recent SIV vaccine trials.


A second focus of Dr. Juelg’s work is the development of small clinical vaccine trials to answer defined immunological questions and to better understand the exact mechanisms and pathways of vaccine-specific T-cell induction.


Dr. Juelg is a physician scientist at the Ragon Institute of MGH, MIT and Harvard and an Instructor in Medicine at Harvard Medical School. He received his M.D. Ph.D. degrees from Christian Albrecht University in Kiel, Germany. He completed a postdoctoral research fellowship with Bruce Walker before undergoing Internal Medicine training at Massachusetts General Hospital followed by a fellowship in Infectious Diseases in the combined program of Massachusetts General Hospital and Brigham and Women’s Hospital.


Publications of Interest

Julg B, Poole D, Ghebremichael M, et al. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012; 7(2):e31161.


Varadarajan N*, Julg B*, Yamanaka YJ, et al.A high-throughput single-cell analysis of human CD8?T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest. 2011 Nov; 121(11):4322-31. *equally contributed.


Streeck H, Kwon DS, Pyo A, Flanders M, Chevalier MF, Law K, Julg, et al. Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. Blood. 2011 May 12; 117(19):5112-22.


Julg B, Moodley ES, Qi Y, et al. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J Infect Dis. 2011 Mar 15; 203(6):803-9.


Chevalier MF*, Julg B*, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011 Jan; 85(2):733-41. *equally contributed.


Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct; 16(10):1147-51.


Julg B, Pereyra F, Buzón MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010 Jul 15; 51(2):233-8.


Julg B, Williams KL, Reddy S, et al. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol. 2010 Jun; 84(11):5540-9.


Julg B, Reddy S, van der Stok M, et al. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. Cell Host Microbe. 2009 May 8; 5(5):413-5


Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009 Apr; 83(7):3138-49.


Laboratory Staff

David Su | davidsu@mgh.harvard.edu

David is working as a research technician with Boris Juelg to elucidate the epigenetic mechanisms involved in long-term programming of memory B cell immunity and plasma cell formation. David graduated from Harvard University with an A. B. in Chemical and Physical Biology in May 2014. He first became interested in disease treatment while designing and synthesizing Alzheimer’s drugs and later wrote his senior thesis on applying microfluidics and polymer physics to model Escherichia coli chromosome condensation. Previously working as a business associate at athenahealth, David is also largely interested in bridging the translational gap between medical technologies and patient care. David prides himself on being born and raised in south Texas. Outside of research, David enjoys competitive ballroom dancing, any outdoor adventures (i.e. surfing, whitewater rafting, etc.), contributing and endorsing charity work, and discussing new ways to invent healthcare solutions.


Julia Torabi | jtorabi@partners.org

Julia is working as a research technician with Boris Juelg. She graduated from the University of Massachusetts Amherst with a B.S. in Biochemistry and Molecular Biology where she wrote her senior thesis on the role of mitotic kinase Aurora A in telophase and cytokinesis of mitosis. Outside of the laboratory Julia plays on a masters water polo team and is an avid fisher.